New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
AI-based app can help physicians find skin melanoma

AI-based app can help physicians find skin melanoma

by Karin Söderlund,Swedish Research CouncilGraph showing the relationships between the primary care physicians' (PCPs') reported degree of melanoma suspicion, final tumor diagnosis and t
Oncology March 30,2024
AI-based app can help physicians find skin melanoma

AI-based app can help physicians find skin melanoma

by Karin Söderlund,Swedish Research CouncilGraph showing the relationships between the primary care physicians' (PCPs') reported degree of melanoma suspicion, final tumor diagnosis and t
Oncology March 30,2024
Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

by Denise Heady,University of California, Los AngelesGraphical Abstract. Credit:Cell Reports Medicine(2024). DOI: 10.1016/j.xcrm.2024.101479A study by researchers at the UCLA Health
Oncology March 30,2024
Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer

by Denise Heady,University of California, Los AngelesGraphical Abstract. Credit:Cell Reports Medicine(2024). DOI: 10.1016/j.xcrm.2024.101479A study by researchers at the UCLA Health
Oncology March 30,2024
Survival 21 percent a year after ICU discharge for blood cancer patients

Survival 21 percent a year after ICU discharge for blood cancer patients

by Elana GotkineFor hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study published onl
Oncology March 30,2024
Survival 21 percent a year after ICU discharge for blood cancer patients

Survival 21 percent a year after ICU discharge for blood cancer patients

by Elana GotkineFor hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study published onl
Oncology March 30,2024
New bioinformatics tool to identify chromosomal alterations in tumor cells

New bioinformatics tool to identify chromosomal alterations in tumor cells

by University of BarcelonaRepresentative output image generated by QATS in which two toroidal nuclei (in magenta) and four micronuclei (in green) were identified. Credit:Bioinformatics&nbsp
Oncology March 30,2024
New bioinformatics tool to identify chromosomal alterations in tumor cells

New bioinformatics tool to identify chromosomal alterations in tumor cells

by University of BarcelonaRepresentative output image generated by QATS in which two toroidal nuclei (in magenta) and four micronuclei (in green) were identified. Credit:Bioinformatics&nbsp
Oncology March 30,2024
Why do cancer patients lose weight? Study points to elevated lactate levels

Why do cancer patients lose weight? Study points to elevated lactate levels

byNature Publishing GroupSchematic illustration depicting the signaling cascade downstream of lactate/GPR81 in promoting cancer cachexia. Credit:Nature Metabolism(2024). DOI: 10.1038
Oncology March 30,2024
Why do cancer patients lose weight? Study points to elevated lactate levels

Why do cancer patients lose weight? Study points to elevated lactate levels

byNature Publishing GroupSchematic illustration depicting the signaling cascade downstream of lactate/GPR81 in promoting cancer cachexia. Credit:Nature Metabolism(2024). DOI: 10.1038
Oncology March 30,2024
Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

by Polish Academy of SciencesOpto-hydrodynamic tweezers. (a) and (b) Schematic illustrations of the top view and side view of OHT, respectively, along with the major various forces acting on the
Oncology March 30,2024
Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

Lu(a)minar flow odyssey—using the power of water and light in early leukemia diagnostics

by Polish Academy of SciencesOpto-hydrodynamic tweezers. (a) and (b) Schematic illustrations of the top view and side view of OHT, respectively, along with the major various forces acting on the
Oncology March 30,2024
Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

by Science China PressSchematic illustration of the construction of conjugates I and II. Schematic illustration of the combinational effects on tumors of the PtIV-MSA-2 conjugates. The PtIV-MSA-2
Oncology March 30,2024
Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

Metalloimmunotherapy: Combination of cisplatin and STING agonist into one molecule boosts cancer immune response

by Science China PressSchematic illustration of the construction of conjugates I and II. Schematic illustration of the combinational effects on tumors of the PtIV-MSA-2 conjugates. The PtIV-MSA-2
Oncology March 30,2024
Mortality among low-risk differentiated thyroid cancer survivors in the US

Mortality among low-risk differentiated thyroid cancer survivors in the US

by Kathryn Ryan,Mary Ann Liebert, IncFlowchart of the study population. Credit:Thyroid(2023). DOI: 10.1089/thy.2023.0449A new study has shown that overall and cause-specific mortalit
Oncology March 30,2024
Mortality among low-risk differentiated thyroid cancer survivors in the US

Mortality among low-risk differentiated thyroid cancer survivors in the US

by Kathryn Ryan,Mary Ann Liebert, IncFlowchart of the study population. Credit:Thyroid(2023). DOI: 10.1089/thy.2023.0449A new study has shown that overall and cause-specific mortalit
Oncology March 30,2024
New treatment option for prostate cancer shows successful outcomes

New treatment option for prostate cancer shows successful outcomes

by The Reis GroupCredit: CC0 Public DomainA minimally-invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to n
Oncology March 30,2024
New treatment option for prostate cancer shows successful outcomes

New treatment option for prostate cancer shows successful outcomes

by The Reis GroupCredit: CC0 Public DomainA minimally-invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to n
Oncology March 30,2024
Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma

Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma

by Molly Chiu,Baylor College of MedicineKaplan-Meier Survival Outcomes of Cancer-Predisposition Variant (CPV) Status on Rhabdomyosarcoma (RMS). Credit:JAMA Network Open(2024). DOI: 1
Oncology March 30,2024
Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma

Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma

by Molly Chiu,Baylor College of MedicineKaplan-Meier Survival Outcomes of Cancer-Predisposition Variant (CPV) Status on Rhabdomyosarcoma (RMS). Credit:JAMA Network Open(2024). DOI: 1
Oncology March 30,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com